MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: Systematic literature review.
Filip Stanicic, Vladimir Zah, Dimitrije Grbic, Djurdja Vukicevic, Debra De Angelo
PLoS One 2025 DOI: 10.1371/journal.pone.0327778 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Placebo-controlled Qualitative Peer reviewed |
|---|---|
| Population | Adults with chronic, treatment-resistant, moderate or higher severity PTSD |
| Interventions | MDMA-assisted therapy venlafaxine ER olanzapine propranolol (with traumatic memory reactivation) nefazodone nabilone cognitive therapy cognitive behavioral therapy cognitive processing therapy prolonged exposure group cognitive exposure therapy |
| Duration | Two or three interventional sessions; long-term follow-up mean duration 45.4 months for MDMA-AT, mean duration 6.2 years for CPT and PE |
| Topics | Psychedelic-assisted therapy PTSD MDMA |
| Keywords | MDMA-Assisted Therapy MDMA-At MDMA Therapy Chronic PTSD Treatment Severe PTSD Treatment Resistant PTSD Treatment Treatment efficacy Treatment effectiveness Durable improvements Loss of diagnosis Remission Recovery Comparative study Treatment comparison Comparative review |
| Citations | 5 |
| Key findings | MDMA-assisted therapy consistently demonstrated greater improvement in PTSD symptoms, depression, and loss of diagnosis compared to placebo with therapy, with durable effects, whereas most current treatments showed heterogeneous evidence without sustained effects. |
Abstract
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) is currently being evaluated for treatment of patients with moderate or higher severity post-traumatic stress disorder (PTSD). To provide a comprehensive summary of investigational MDMA-AT and current treatments for PTSD. A search was conducted in PubMed and Embase (December 20, 2023). Populations included adults with chronic, treatment-resistant, moderate or higher severity PTSD. Interventions were MDMA-AT and comparators based on PTSD treatment guidelines. The primary outcome of interest was the Clinician-Administered PTSD Scale (CAPS) score. Other outcomes observed were Beck Depression Inventory (BDI), and loss of diagnosis (LOD). Studies observing chronic, moderate or higher severity treatment-resistant PTSD in adults were included. Only randomized controlled trials published in English were considered. The NICE quality appraisal checklist was used to assess risk of bias in included studies. We provided qualitative synthesis of evidence presented in extraction tables. Overall, 77 studies were included. Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. Durability was observed in a long-term follow-up trial (mean duration, 45.4 months) with a 0.9-point CAPS decrease from post-treatment. FDA-approved and off-label medications used for PTSD treatment did not yield a consistently greater CAPS decrease vs. control arms across trials. Significant CAPS improvement was consistently observed in venlafaxine ER, olanzapine, propranolol (with traumatic memory reactivation), nefazodone, and nabilone placebo-controlled trials. Most psychotherapy trials lacked between-group statistical assessments. Significant CAPS decrease compared to the waitlist was reported for cognitive therapy (CT), cognitive behavioral therapy (CBT), cognitive processing therapy (CPT), prolonged exposure (PE), and group cognitive exposure therapy. CAPS improvement was persistent for CPT and PE in long-term follow up (mean duration 6.2 years). MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). The percentage of participants with LOD after two or three active-dose MDMA-AT sessions ranged from 41.7-83.3%. This systematic review suggests current treatments for PTSD are associated with heterogeneous evidence and the majority do not demonstrate sustained effects. Results from MDMA-AT showed consistent improvements in CAPS, BDI and LOD.
Comparable studies
Other systematic reviews and meta-analyses on MDMA and psychedelic-assisted therapy, most cited first.
Citations in the library
Cited by 5
- Exploring critical psychedelic phenomenology: What Frantz Fanon can teach us about psychedelic therapy for racialized and colonized people Psychedelics August 15, 2026
- Policy Considerations for Psychedelics in Research and Medicine – What’s Next on the Schedule? Journal of Science Policy & Governance July 2, 2026
- Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes European Neuropsychopharmacology March 12, 2026
- A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder Current Treatment Options in Psychiatry December 26, 2025
- The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives. Pharmacology, Biochemistry, and Behavior November 1, 2025
Cites 12
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Journal of Psychopharmacology October 31, 2012
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
and 7 more in the library